CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
REVENUE
Products, net	$ 197,554	$ 18,054
Services		27,500
Total Revenue	197,554	45,554
COST OF REVENUE, PRODUCT	155,549	6,391
GROSS MARGIN	42,005	39,163
EXPENSES
Sales and marketing	356,948	16,899
General and administrative	953,484	141,862
Reverse merger costs		376,366
Depreciation and Amortization	224,770	19,956
Impairment of asset	893,667
TOTAL OPERATING EXPENSES	2,428,869	555,083
NET LOSS	(2,386,864)	(515,920)
Less: Net loss attributable to non controlling interest	10,763	(1,736)
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.	$ (2,376,101)	$ (517,656)
LOSS PER COMMON SHARE	$ (0.16)	$ (0.04)
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic and diluted	15,071,417	12,046,644